Montelukast Teva (Montelukast Sodium)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition stops the cascade that leads to bronchoconstriction, mucus secretion, and airway edema, thereby improving breathing and reducing allergic symptoms.

The dose of Montelukast Teva is determined by the prescribing healthcare professional based on the patient’s age, condition and clinical response. The prescriber will select the appropriate strength and dosing schedule, which may differ for asthma, allergic rhinitis or exercise‑induced bronchoconstriction.

Safety data for Montelukast during pregnancy are limited, and the drug should only be used if the potential benefit justifies any possible risk to the fetus. Limited information suggests that small amounts are excreted in breast milk; therefore, a risk‑benefit assessment is required before use in nursing mothers.

To place an order, submit an enquiry on the Montelukast Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a non‑inhaled option. While it may be less potent than high‑dose inhaled steroids for severe asthma, it provides valuable add‑on therapy and benefits for allergic rhinitis.

Montelukast Teva tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain stability throughout its shelf life.

Montelukast Teva is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, and the timing (e.g., in the evening for asthma) is determined by the prescribing clinician based on the therapeutic goal.

The most serious risks include neuropsychiatric events such as agitation, depression, suicidal thoughts or behaviours, and severe allergic reactions like anaphylaxis, Stevens‑Johnson syndrome or angio‑edema. Patients should be instructed to seek immediate medical attention if they experience mood changes, rash, swelling or breathing difficulties.

Montelukast Teva is contraindicated in individuals with known hypersensitivity to Montelukast sodium or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, and it should be avoided in those who have experienced serious neuropsychiatric or allergic reactions to the drug.